Symbio Of Japan Obtains Clinical Study Rights From Cephalon Affiliate
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Symbio obtained the rights to commence Japanese domestic clinic trials for Lupuzor for systemic lupus erythematosus from the Swiss affiliate of U.S.-based Cephalon